eyepoint
pharmaceuticals
reports
third
quarter
financial
results
highlights
recent
corporate
developments
total
revenues
million
net
product
revenues
million
sequential
quarterly
increase
underlying
customer
demand
potential
sustained
delivery
intravitreal
treatment
targeting
wet
macular
degeneration
remains
track
ind
filing
crg
debt
facility
amended
waiving
modifying
net
product
revenue
covenants
respectively
cash
october
million
management
host
conference
call
webcast
today
et
watertown
globe
newswire
eyepoint
pharmaceuticals
nasdaq
eypt
pharmaceutical
company
committed
developing
commercializing
innovative
ophthalmic
products
today
announced
financial
results
third
quarter
ended
september
highlighted
recent
corporate
developments
continued
increase
patient
office
visits
resumption
operations
many
healthcare
facilities
quarter
encouraged
see
customer
demand
near
pandemic
levels
said
nancy
lurker
president
chief
executive
officer
eyepoint
pharmaceuticals
enter
remaining
months
eyepoint
imprimisrx
combined
sales
teams
mobilized
promote
dexycu
established
account
base
yutiq
team
continuing
call
uveitis
retinal
physician
offices
subject
evolving
lurker
continued
recent
completion
good
laboratory
practice
glp
toxicology
study
potential
sustained
delivery
intravitreal
treatment
wet
macular
degeneration
wet
amd
remain
track
submit
investigational
new
drug
ind
application
end
year
upon
acceptance
ind
food
drug
administration
fda
look
forward
initiating
phase
trial
wet
amd
eye
disease
significant
need
treatment
options
may
slow
progression
addition
continue
diligently
manage
cash
burn
rate
ended
october
million
commercial
performance
third
quarter
customer
demand
yutiq
represented
units
purchased
physicians
company
distributors
approximately
units
compared
approximately
units
customer
demand
dexycu
represented
units
purchased
ambulatory
surgery
centers
ascs
company
distributors
approximately
units
compared
approximately
units
separate
purchasing
marketing
agreements
expanded
access
dexycu
across
recently
executed
vantage
outsourcing
another
undisclosed
healthcare
network
company
actively
negotiating
agreements
additional
group
purchasing
organizations
networks
august
company
imprimisrx
signed
commercial
alliance
joint
promotion
dexycu
doubles
size
team
engaging
directly
physicians
ascs
september
imprimisrx
sales
specialists
inside
sales
team
completed
product
training
positioned
call
ophthalmologist
hospital
asc
accounts
company
continues
actively
monitor
pandemic
associated
public
health
recommendations
ensure
safety
patients
physicians
employees
operations
update
october
based
part
return
customer
demand
products
following
closures
company
secured
amendment
existing
debt
facility
crg
servicing
llc
crg
crg
waived
covenant
associated
company
net
product
revenue
dexycu
yutiq
period
ending
december
crg
also
agreed
reduction
calendar
year
net
product
revenue
covenant
million
million
material
changes
made
term
loan
agreement
company
incurred
incremental
charges
connection
amendment
august
company
ocumension
therapeutics
announced
expansion
exclusive
license
agreements
yutiq
dexycu
certain
markets
asia
expanded
agreements
ocumension
made
million
payment
eyepoint
rights
commercialize
products
brand
names
south
korea
jurisdictions
across
southeast
asia
full
final
payment
remaining
development
regulatory
commercial
sale
milestone
payments
original
license
agreements
royalties
future
product
sales
remain
payable
company
pursuant
license
agreements
r
highlights
october
company
completed
glp
toxicology
study
potential
sustained
delivery
intravitreal
treatment
using
bioerodible
technology
wet
amd
company
expects
file
ind
application
fda
fourth
quarter
phase
human
clinical
trial
commence
shortly
ind
acceptance
fda
review
results
third
quarter
ended
september
three
months
ended
september
total
net
revenue
million
compared
million
three
months
ended
september
net
product
revenue
three
months
ended
september
million
million
yutiq
million
dexycu
compared
net
product
revenue
three
months
ended
september
million
generated
primarily
dexycu
net
product
revenue
represents
product
purchased
eyepoint
distributors
whereas
customer
demand
represents
purchases
product
physician
practices
ascs
eyepoint
distributors
net
revenue
licenses
royalties
collaborations
three
months
ended
september
totaled
million
compared
million
corresponding
quarter
operating
expenses
three
months
ended
september
totaled
million
compared
million
prior
year
period
increase
driven
million
increase
cost
sales
million
increase
g
expense
million
increase
r
expense
offset
million
reduction
sales
marketing
expense
expense
net
three
months
ended
september
totaled
million
net
interest
expense
net
loss
three
months
ended
september
million
per
share
compared
net
loss
million
per
share
prior
year
quarter
review
nine
months
results
ended
september
nine
months
ended
september
total
net
revenue
million
compared
million
nine
months
ended
september
net
product
revenue
nine
months
ended
september
million
compared
net
product
revenues
nine
months
ended
september
million
net
revenue
royalties
collaborations
nine
months
ended
september
totaled
million
compared
million
corresponding
period
operating
expenses
nine
months
ended
september
totaled
million
million
prior
year
period
increase
primarily
due
million
increase
cost
sales
million
increase
r
expense
million
increase
g
expense
offset
million
decrease
sales
marketing
expense
expense
net
nine
months
ended
september
totaled
million
net
loss
nine
months
ended
september
million
per
share
compared
net
loss
million
per
share
prior
year
period
cash
cash
equivalents
october
totaled
million
compared
million
september
million
december
financial
outlook
expect
company
cash
cash
equivalents
combined
projected
cash
inflows
anticipated
yutiq
dexycu
product
sales
expected
financing
activities
fund
company
operating
plan
assuming
significant
increase
closures
would
materially
affect
frequency
ophthalmology
office
visits
number
cataract
surgical
procedures
performed
across
company
continues
assess
additional
cash
conservation
generation
measures
support
operations
pandemic
conference
call
information
eyepoint
host
conference
call
today
thursday
november
et
discuss
results
third
quarter
ended
september
recent
operational
developments
access
conference
call
please
dial
canada
international
least
minutes
prior
start
time
refer
conference
id
live
webcast
available
investor
relations
section
corporate
website
http
replay
webcast
also
available
corporate
website
eyepoint
pharmaceuticals
eyepoint
pharmaceuticals
pharmaceutical
company
committed
developing
commercializing
innovative
ophthalmic
products
indications
high
unmet
medical
need
help
improve
lives
patients
serious
eye
disorders
company
currently
two
commercial
products
first
approved
intraocular
product
treatment
postoperative
inflammation
treatment
chronic
uveitis
affecting
posterior
segment
eye
company
pipeline
leverages
proprietary
bioerodible
technology
extended
intraocular
drug
delivery
including
potential
sustained
delivery
intravitreal
treatment
initially
targeting
wet
macular
degeneration
eyepoint
pharmaceuticals
headquartered
watertown
massachusetts
offices
basking
ridge
new
jersey
learn
company
please
visit
connect
twitter
linkedin
safe
harbor
statements
private
securities
litigation
act
various
statements
made
release
inherently
subject
risks
uncertainties
potentially
inaccurate
assumptions
statements
address
activities
events
developments
intend
expect
plan
believe
may
occur
future
including
limited
statements
expectations
regarding
extent
business
could
adversely
impacted
effects
coronavirus
pandemic
well
timing
clinical
development
product
candidates
including
potential
vital
novel
treatment
wet
macular
degeneration
factors
could
cause
actual
results
differ
materially
anticipated
results
expectations
expressed
anticipated
implied
statements
risks
uncertainties
inherent
business
including
without
limitation
extent
impacts
business
effectiveness
timeliness
clinical
trials
usefulness
data
timeliness
regulatory
approvals
ability
achieve
profitable
operations
access
needed
capital
fluctuations
operating
results
ability
successfully
produce
sufficient
commercial
quantities
yutiq
dexycu
successfully
commercialize
yutiq
dexycu
ability
sustain
enhance
effective
commercial
infrastructure
enter
maintain
commercial
agreements
yutiq
dexycu
development
yutiq
line
extension
treatment
uveitis
affecting
posterior
segment
eye
potential
sales
iluvien
uveitis
affecting
posterior
segment
eye
consequences
fluocinolone
acetonide
side
effects
yutiq
consequences
dexamethasone
side
effects
dexycu
successful
commercialization
receipt
revenues
iluvien
diabetic
macular
edema
dme
alimera
ability
obtain
additional
marketing
approvals
effect
pricing
reimbursement
decisions
sales
iluvien
dme
alimera
ability
commercialize
iluvien
uveitis
affecting
posterior
segment
eye
territories
alimera
licensed
ability
market
sell
products
success
current
future
license
agreements
including
agreement
equinox
science
termination
breach
current
license
agreements
including
agreement
equinox
science
dependence
contract
research
organizations
contract
sales
organizations
vendors
investigators
effects
competition
developments
affecting
sales
products
market
acceptance
products
effects
guidelines
recommendations
studies
protection
intellectual
property
avoiding
intellectual
property
infringement
retention
key
personnel
product
liability
industry
consolidation
compliance
environmental
laws
manufacturing
risks
risks
costs
international
business
operations
volatility
stock
price
possible
dilution
absence
dividends
factors
described
filings
securities
exchange
commission
guarantee
results
expectations
expressed
anticipated
implied
statement
realized
variety
factors
including
risks
could
cause
actual
results
expectations
differ
materially
anticipated
results
expectations
expressed
anticipated
implied
statements
known
unknown
risks
materialize
underlying
assumptions
prove
inaccurate
actual
results
could
differ
materially
past
results
anticipated
estimated
projected
statements
bear
mind
consider
statements
statements
speak
dates
made
undertake
obligation
publicly
update
revise
statements
even
experience
future
changes
makes
clear
projected
results
expressed
implied
statements
realized
contacts
investors
argot
partners
sam
martin
joe
rayne
eyepoint
media
thomas
gibson
tom
eyepoint
pharmaceuticals
subsidiaries
condensed
consolidated
statements
operations
unaudited
thousands
except
per
share
data
three
months
ended
nine
months
ended
september
september
revenues
product
sales
net
license
collaboration
agreements
royalty
income
total
revenues
operating
expenses
cost
sales
excluding
amortization
acquired
intangible
assets
research
development
sales
marketing
general
administrative
amortization
acquired
intangible
assets
total
operating
expenses
loss
operations
income
expense
interest
income
net
interest
expense
loss
extinguishment
debt
total
expense
net
net
loss
net
loss
per
common
share
basic
diluted
weighted
average
common
shares
outstanding
basic
diluted
eyepoint
pharmaceuticals
subsidiaries
condensed
consolidated
balance
sheets
unaudited
thousands
september
december
assets
current
assets
cash
cash
equivalents
accounts
receivables
net
prepaid
expenses
current
assets
inventory
total
current
assets
operating
lease
assets
intangible
assets
net
assets
total
assets
liabilities
stockholders
equity
current
liabilities
accounts
payable
accrued
expenses
current
liabilities
deferred
revenue
total
current
liabilities
debt
operating
lease
liabilities
noncurrent
portion
liabilities
total
liabilities
stockholders
equity
capital
accumulated
deficit
accumulated
comprehensive
income
total
stockholders
equity
total
liabilities
stockholders
equity
